美疾控中心批準Moderna及強生疫苗作爲新冠疫苗加強劑
美國疾控中心(CDC)批準Moderna(MRN.US)及強生(JNJ.US)各自生產的新冠疫苗作爲加強劑,並允許混合使用三款已獲當局批準使用的疫苗。
美國疾控中心顧問小組昨日(21日)早上一致同意上述兩款疫苗作爲新冠疫苗加強劑使用。中心的防疫顧問小組建議:已完成接種Moderna疫苗的長者及高危羣組人士,可在接種第二劑後半年接種第三劑,與早前獲批準作加強劑的「復必泰」疫苗相同。小組亦批準已接種強生一劑過疫苗的18歲或以上人士,可在完成接種後兩個月後接種加強劑。
小組沒有指定已接種特定疫苗人士須接種同款疫苗作爲加強劑,意味醫生可隨意決定是否讓病人混合使用疫苗,即「溝針」。
據有關會議簡報文件,美國有逾3,900萬名已完成接種Moderna疫苗人士,以及近1,300萬名已接種強生疫苗人士,合資格接種加強劑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.